Advances in stroke 2003: introduction.
Hachinski
Vladimir
V
London Sciences Health Centre, University of Western Ontario, London, Ontario, Canada.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000235:genetics; D017130:Angioplasty / Q000639:trends; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D002340:Carotid Artery Diseases / Q000150:complications / Q000000981:diagnostic imaging; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020022:Genetic Predisposition to Disease; D006801:Humans; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000209:etiology / Q000235:genetics / Q000628:therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use; D014463:Ultrasonography
D000806:Angiotensin-Converting Enzyme Inhibitors; D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D010959:Tissue Plasminogen Activator